Panayiotis Panayiotidis

National and Kapodistrian University of Athens — Greece

Medicine · Health Sciences

40h-index7.3kcitations288works6.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(128), Lymphoma Diagnosis and Treatment(112), Acute Myeloid Leukemia Research(43), Multiple Myeloma Research and Treatments(37), Chronic Myeloid Leukemia Treatments(37)

Publications286 total

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
The Lancet·2025· 6 cited
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Blood Advances·2025Open Access
Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview
Cancers·2025Open Access
Validation of the simplified geriatric prognostic index in a Hellenic database of older patients (≥ 70 years old) with diffuse large B-cell lymphoma and similar disorders
Annals of Hematology·2025Open Access
Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform
Leukemia & lymphoma/Leukemia and lymphoma·2025
134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY
Hematological Oncology·2025· 1 citedOpen Access
28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Hematological Oncology·2025Open Access
344 | SERUM β2‐ MICROGLOBULIN LEVELS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: AN UNRECOGNIZED PROGNOSTIC FACTOR
Hematological Oncology·2025Open Access
Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had <i>TP53</i> mutations in the SYMPATICO study.
Journal of Clinical Oncology·2025
Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance
Leukemia & lymphoma/Leukemia and lymphoma·2025· 2 cited
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic &amp; Hypoplastic Syndromes Registry (EAKMYS)
Cancers·2025· 2 citedOpen Access
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
Blood·2024· 17 cited
Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
Blood·2024Open Access
Disease Bulk and/or Very High LDH As Adverse Factors in IPI 1-2 Diffuse Large B-Cell Lymphoma (DLBCL): A Hellenic Database Validation of the LEO Cohort
Blood·2024· 1 citedOpen Access
Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Steroids (PolaRCHP) in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Real-Life Experience in Greece
Blood·2024
Therapeutic Strategies and Outcomes in Patients with Chronic Myeloid Leukemia: A Real World Study
Blood·2024Open Access
The Prognostic Significance of Serum β2- Microglobulin Levels (sβ2m) in Diffuse Large B-Cell Lymphoma (DLBCL)
Blood·2024· 1 citedOpen Access
The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia
American Journal of Hematology·2024· 13 citedOpen Access
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification
Leukemia & lymphoma/Leukemia and lymphoma·2024· 2 cited
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Leukemia·2024· 6 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Meletios Α. Dimopoulos(12), Maria K. Angelopoulou(10), Theodoros P. Vassilakopoulos(9), Gerassimos A. Pangalis(9), Maria Dimou(8), Christina Kalpadakis(8), Marina P. Siakantaris(8), Maria Pagoni(6), Marie‐Christine Kyrtsonis(6), Susanne Saußele(5), Andreas Hochhaus(5), Sotirios Sachanas(5), Evangelos Terpos(5), Penelope Korkolopoulou(5), Andrew H. Wei(4), Pau Montesinos(4), Vladimir Ivanov(4), Courtney D. DiNardo(4), Jan Novák(4), Inho Kim(4)